Login to Your Account



Novartis nabs Selexys for potential $665M, gains phase II agent for SCD

By Marie Powers
News Editor

Monday, November 21, 2016

Less than two weeks before the start of the ASH annual meeting, Novartis AG nabbed under-the-radar biotech Selexys Pharmaceuticals Corp. for up to $665 million in up-front, acquisition and milestone payments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription